Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200mcg and 100mcg, Once Daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 6 to 11 Years of Age.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Dec 2016
Price :
$35
*
At a glance
- Drugs Ciclesonide (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors ALTANA Pharma
- 04 May 2012 Company added in the association field and additional lead trial centre identified as reported by ClinicalTrials.gov.
- 07 Jun 2011 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
- 19 Dec 2006 Status change